Literature DB >> 1614416

Transfection of human 5-hydroxytryptamine1A receptors in NIH-3T3 fibroblasts: effects of increasing receptor density on the coupling of 5-hydroxytryptamine1A receptors to adenylyl cyclase.

A Varrault1, L Journot, Y Audigier, J Bockaert.   

Abstract

Human serotonin [5-hydroxytryptamine (5-HT)1A] receptors have been transfected in NIH-3T3 cells, and their pharmacology and coupling to adenylyl cyclase have been analyzed. Three cellular preparations were used, 1) monoclonal cell lines (clones 6, 2B, and 4B), expressing 45, 280, and 500 fmol of 5-HT1A receptors/mg of protein, respectively; 2) clones 6, 2B, and 4B in which the concentration of 5-HT1A receptors was increased after stimulation of the glucocorticoid-inducible promoter with dexamethasone; and 3) polyclonal cell lines that expressed an increasing amount of 5-HT1A receptor as a function of cell passage. The transfected 5-HT1A receptors inhibited basal, forskolin-stimulated, and isoproterenol-stimulated adenylyl cyclase. The inhibition was dependent on the receptor density expressed, increasing from 60% at low density (45 fmol/mg) to 90% at a density higher than 280 fmol/mg. The pharmacology of the 5-HT1A receptor was studied, with particular attention being paid to the behavior of some agonists. These pharmacological characteristics are similar to those of 5-HT1A receptors in hippocampus but different from those of 5-HT1A in cerebral cortex. Analysis of the potencies and efficacies of the full agonist 5-HT and the partial agonist ipsapirone, as a function of receptor density in the three cellular populations used, revealed that 1) the efficacies of the full and partial agonists increased with the receptor density; 2) the EC50 values of the full and partial agonists were not shifted to the left when the receptor density was increased (based on the increase in efficacy and considering the classical pharmacological models of receptor-drug action, a 9-10-fold shift was expected); and 3) the ratio between the efficacies of the full agonist 5-HT and the partial agonist ipsapirone was not modified when the receptor concentration was increased or when the GTP-binding protein availability was decreased. The results indicate that neither the classical nor the operational model of drug-receptor action can be used to describe the coupling of 5-HT1A receptors to adenylyl cyclase in transfected NIH-3T3 cells. One of the explanations could be that 5-HT1A receptors and GTP-binding proteins are coupled in functional domains (almost precoupled), rather than distributed in homogeneous compartments in which they are free to diffuse.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1614416

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  16 in total

Review 1.  The recombinant 5-HT1A receptor: G protein coupling and signalling pathways.

Authors:  J R Raymond; Y V Mukhin; T W Gettys; M N Garnovskaya
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Modulation of 5-HT(1A) receptor-mediated Ca(2+) responses by co-expression with various recombinant G(alpha) proteins in CHO-K1 cells.

Authors:  Thierry Wurch; Petrus J Pauwels
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-07-16       Impact factor: 3.000

3.  Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D₂ and D₃ Receptors.

Authors:  Maarten E A Reith; Aloke K Dutta; Dana E Selley; Juan Zhen; Tamara Antonio; Joanna C Jacob; David K Grandy
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

4.  Ligand efficacy and potency at recombinant human MT2 melatonin receptors: evidence for agonist activity of some mt1-antagonists.

Authors:  R Nonno; M Pannacci; V Lucini; D Angeloni; F Fraschini; B M Stankov
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

5.  Pharmacological characterizations of recombinant human 5-HT1D alpha and 5-HT1D beta receptor subtypes coupled to adenylate cyclase inhibition in clonal cell lines: apparent differences in drug intrinsic efficacies between human 5-HT1D subtypes.

Authors:  J M Zgombick; L E Schechter; N Adham; S A Kucharewicz; R L Weinshank; T A Branchek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

6.  Variable Dependence of Signaling Output on Agonist Occupancy of Ste2p, a G Protein-coupled Receptor in Yeast.

Authors:  Rajashri Sridharan; Sara M Connelly; Fred Naider; Mark E Dumont
Journal:  J Biol Chem       Date:  2016-09-19       Impact factor: 5.157

7.  Serotonin depletion hampers survival and proliferation in neurospheres derived from adult neural stem cells.

Authors:  Jens Benninghoff; Angela Gritti; Matteo Rizzi; Giuseppe Lamorte; Robert J Schloesser; Angelika Schmitt; Stefanie Robel; Just Genius; Rainald Moessner; Peter Riederer; Husseini K Manji; Heinz Grunze; Dan Rujescu; Hans-Juergen Moeller; Klaus-Peter Lesch; Angelo Luigi Vescovi
Journal:  Neuropsychopharmacology       Date:  2009-12-09       Impact factor: 7.853

8.  BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex.

Authors:  F Borsini; E Giraldo; E Monferini; G Antonini; M Parenti; G Bietti; A Donetti
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-09       Impact factor: 3.000

9.  Cell-specific coupling of the cloned human 5-HT1F receptor to multiple signal transduction pathways.

Authors:  N Adham; L A Borden; L E Schechter; E L Gustafson; T L Cochran; P J Vaysse; R L Weinshank; T A Branchek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

10.  Differential sensitivity of 3H-agonist binding to pre- and postsynaptic 5-HT1A receptors in bovine brain.

Authors:  L G Iben; C D Mahle; F D Yocca
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.